Kiniksa Pharmaceuticals International, plc KNSA Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's accrued liabilities, current?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported accrued liabilities, current of $32.77M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's accrued liabilities, current changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's accrued liabilities, current increased by 48.1% year-over-year, from $22.13M to $32.77M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's accrued liabilities, current?
- Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's accrued liabilities, current has grown at a 7.6% compound annual growth rate (CAGR), from $29.2M to $42.02M.